- Home
- FSP vs MCRB Comparison
FSP vs MCRB Comparison
Compare FSP & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FSP | MCRB |
|---|---|---|
| Founded | 1981 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 71.0M |
| IPO Year | 2001 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FSP | MCRB |
|---|---|---|
| Price | $0.52 | $7.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.2M | 107.2K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | ★ 15.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,162,000.00 | $789,000.00 |
| Revenue This Year | $17.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $5.31 |
| 52 Week High | $1.82 | $29.98 |
Technical Indicators
Market Signals| Indicator | FSP | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 58.91 |
| Support Level | $0.50 | $6.56 |
| Resistance Level | $0.71 | $8.29 |
| Average True Range (ATR) | 0.04 | 0.62 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 6.01 | 87.27 |
Price Performance
Historical ComparisonAbout FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.